I was born in the mountains of 🇻🇳. At 5 my parents sought the land of opportunity 🇺🇸. This Dec our family reunited in 🇻🇳. My country has changed and so have we. Change = opportunity. From my Fam: Happy new years! With the change, I hope you also find your opportunities to grow.

🔸Your most enduring professional legacy is not your CV — there will always be others with more papers, earnings, awards. Your most enduring professional legacy is... ...the people you've mentored. ▪️January is #NationalMentoringMonth.▪️Take time to celebrate your #oncology

My story. I review it from time to time to ask if I am the same author today. A time capsule of myself. From strawberries to stethoscopes: lessons in humanity from a future oncologist kevinmd.com/2025/01/from-s… via Kevin Pho, M.D.

"Make a career of humanity. Commit yourself to the noble struggle for equal rights. You will make a better person of yourself, a greater nation of your country, and a finer world to live in." - MLK Jr I celebrate all of you living on his legacy by making a career of humanity.

I make no generational judgement—disheartening to see burnout at all. Especially a field that clearly still holds joy for those that practice. The landscape is not what it used to be & we’ve trained to be nimble with medical decision—not staffing, prior auth, or EMR burden.

What a weekend catching up with close friends, meeting with inspiring leaders, and chatting with fellows about how to navigate life as oncology attendings. Huge thanks to @Precisca for this distinctive annual tradition!

Thank you OncLive.com for the opportunity to share some insights on treatment landscape for #mTNBC and highlight some of the promising ongoing studies.

Not everything fits cleanly in guidelines Real-world experience matters Experts respond quickly If you're in oncology, it's worth trying Primum for fast curbside consults: app.primum.co/create-account…

Camizestrant could reshape how we monitor and manage patients. “If a patient is found to have an #ESR1 mutation, the question [of SERENA-6] is whether we should switch aromatase inhibitors….We know that hormone-blocking therapies do not work well in this scenario. If we were to

What a thought provoking and stimulating ASCO for the breast cancer community! Still processing it all and looking forward hearing what others think of SERENA-6, DB-09, ASCENT-04 and beyond. #ASCO25 #CleClinicCancer

It's the last day of ASCO #ASCO25 and the last day of #OntheClock ⏱️ with MedNews Week. In this clip, MinhTri Nguyen, MD, of Stanford Health Care, discusses the SERENA6 data with Yan Leyfman, MD Did he beat the clock? 👀

Had a chance to speak with CancerNetwork alongside Eric K. Singhi, MD, MinhTri Nguyen, MD (he/him), Nerea Lopetegui-Lia, MD and Marc Braunstein, MD, PhD, FACP about one of the most underdiscussed—and overwhelming—periods in our careers: preparing for the boards while transitioning from fellowship to faculty. The facts: 📚

Stanford paid 35,000 people to quit social media. This was the largest study on emotional health in history. The results were so shocking, scientists called it "comparable to therapy." Here's what happens when you break free from the algorithm: 🧵

Evaluation and Treatment of Iron Deficiency for the Practicing Oncologist | JCO Oncology Practice ascopubs.org/doi/10.1200/OP… JCO Oncology Practice ASCO Journal of Clinical Oncology OncoAlert

Happening Now. Dana-Farber’s Breast Oncology Center and Dr. Waks debates standard of care in Stage II/III Her2+ Breast Cancer. Carboplatin addition to taxane HP does not improve pCR. EFS data still outstanding. Neuropathy worse with weekly abraxane, HP for 18 weeks than TCHP.

The journey from resident or fellow to a board-certified attending oncologist is a multifaceted and often daunting endeavor. Eric K. Singhi, MD Nicholas Hornstein Marc Braunstein, MD, PhD, FACP Nerea Lopetegui-Lia, MD MinhTri Nguyen, MD (he/him) cancernetwork.com/view/navigatin…

It was a privilege to work on this review with you Kimmie Ng, MD, MPH We highlight the rise in young-onset gastrointestinal cancers—current understanding, practical considerations, and future directions.

A subset of patients with HER2+ metastatic breast cancer are cured by current therapies. Can we increase the rate of cured patients with patient selection & sequential use of the best anti-HER2 agents currently available? High hopes in the #SAPPHO phase 2 trial to bring answers.

Very big news out today-- adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 yrs of f/u! Showing OS benefit in this setting is not easy & nice to see what an incredible impact adj cdk4/6i can have for our patients! prnewswire.com/news-releases/…

1/2📢Now out in The Lancet Oncology 📢 🔹Burnout now impacts 𝟱𝟵% of U.S. oncologists—up from 45% in 2013. This is no longer just a workforce issue—it’s a patient care crisis. 🔹Proud to join ASCO, COSA & European Cancer Organisation in this global call to action for thriving,